CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and olde ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

As long as a drug shortage is declared, compounding pharmacies are still eligible to produce their own versions of Zepbound/Mounjaro. HealthDay News — The US Food and Drug Administration re ...

Credit: Celltrion Steqeyma, formerly known as CT-P43, is a human interleukin-12 and -23 antagonist. According to Celltrion, Steqeyma is expected to be available in February 2025. The Food and Drug ...

Vitamin D supplementation, with or without calcium, offers no benefit for preventing falls or fractures in community-dwelling seniors and may increase risk of kidney stones. HealthDay News — The ...

Although age-standardized stroke mortality rates have increased in some areas, during the past 3 decades age-standardized stroke burden rates have declined worldwide. Across the last 3 decades ...